Viatris Inc
A global healthcare company that makes and sells generic medicines, complex drugs, and iconic brand-name products like Lipitor® and Lyrica®, reaching hundreds of millions of patients across more than a hundred countries. Viatris was created in 2020 when the drugmaker Mylan merged with Upjohn, the off-patent medicines arm of Pfizer, uniting two long pharmaceutical histories. It has since streamlined by selling off its women's health, over-the-counter, and active-ingredient businesses.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| DAVIS SELECTED ADVISERS | 13G/APassive | 6.5% | 75.23M | Aug 12, 2026 |
| FMR LLC | 13GPassive | 8.3% | 96.36M | Aug 6, 2026 |
| Abigail P. Johnson | 13GPassive | 8.3% | 96.36M | Aug 6, 2026 |
| Vanguard Capital Management | 13GPassive | 7.36% | 84.81M | Apr 30, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| BlackRock, Inc. | 13G/APassive | 6.6% | 76.38M | Oct 17, 2025 |
| STATE STREET CORPORATION | 13GPassive | 4.7% | 55.29M | Aug 11, 2025 |
| T. Rowe Price Associates, Inc. | 13GPassive | 6.3% | 74.72M | May 14, 2025 |